A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine
- 9 May 2013
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 31 (30), 3039-3045
- https://doi.org/10.1016/j.vaccine.2013.04.071
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple SclerosisJournal of Interferon & Cytokine Research, 2010
- Follicular dendritic cell networks of primary follicles and germinal centers: Phenotype and functionSeminars in Immunology, 2008
- Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young AdultsThe Journal of Infectious Diseases, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- EBV the prototypical human tumor virus—just how bad is it?Journal of Allergy and Clinical Immunology, 2005
- Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNAVaccine, 1995
- The CD19/CR2/TAPA-1 Complex of B Lymphocytes: Linking Natural to Acquired ImmunityAnnual Review of Immunology, 1995
- Construction of bacteriophage expressing mouse monoclonal Fab fragments directed against the human MN glycophorin blood group antigensTransfusion, 1995
- Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic moleculesVaccine, 1994
- Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.The Journal of Experimental Medicine, 1991